![]()
|
|
||||||||
J. Biol. Chem., Vol. 280, Issue 16, 16305-16310, April 22, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

¶
¶
||**
From the
Departments of
Pharmacology and ||Neuroscience, The Johns Hopkins School of Medicine, Baltimore, Maryland 21205 and Departments of
Molecular Biology and ¶Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037
Myelin-associated glycoprotein (MAG, Siglec-4) is one of several endogenous axon regeneration inhibitors that limit recovery from central nervous system injury and disease. Molecules that block such inhibitors may enhance axon regeneration and functional recovery. MAG, a member of the Siglec family of sialic acid-binding lectins, binds to sialoglycoconjugates on axons and particularly to gangliosides GD1a and GT1b, which may mediate some of the inhibitory effects of MAG. In a prior study (Blixt, O., Collins, B. E., van den Nieuwenhof, I. M., Crocker, P. R., and Paulson, J. C. (2003) J. Biol. Chem. 278, 31007-31019), we identified potent monovalent sialoside inhibitors of MAG using a novel screening platform. In the current study, the most potent of these were tested for their ability to reverse MAG-mediated inhibition of axon outgrowth from rat cerebellar granule neurons in vitro. Monovalent sialoglycans enhanced axon regeneration in proportion to their MAG binding affinities. The most potent glycoside was disialyl T antigen (NeuAc
23Gal
13[NeuAc
26]GalNAc-R), followed by 3-sialyl T antigen (NeuAc
23Gal
13GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides. Prior studies indicated that blocking gangliosides reversed MAG inhibition (Vyas, A. A., Patel, H. V., Fromholt, S. E., Heffer-Lauc, M., Vyas, K. A., Dang, J., Schachner, M., and Schnaar, R. L. (2002) Proc. Natl. Acad. Sci. USA 99, 84128417). In the current study, blocking O-linked glycoprotein sialylation with benzyl-
-GalNAc had no effect. The ability to reverse MAG inhibition with monovalent glycosides encourages further exploration of glycans and glycan mimetics as blockers of MAG-mediated axon outgrowth inhibition.
Received for publication, January 7, 2005 , and in revised form, February 3, 2005.
* This work was supported by NINDS Grant NS37096 and NIGMS Grant GM60938 from the National Institutes of Health, United States Public Health Service. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
** To whom correspondence should be addressed: Dept. of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205. Tel.: 410-955-8392; Fax: 410-955-4900; E-mail: schnaar{at}jhu.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Z. Cao, J. Qiu, M. Domeniconi, J. Hou, J. B. Bryson, W. Mellado, and M. T. Filbin The Inhibition Site on Myelin-Associated Glycoprotein Is within Ig-Domain 5 and Is Distinct from the Sialic Acid Binding Site J. Neurosci., August 22, 2007; 27(34): 9146 - 9154. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. S. Yang, I. Lorenzini, K. Vajn, A. Mountney, L. P. Schramm, and R. L. Schnaar Sialidase enhances spinal axon outgrowth in vivo PNAS, July 18, 2006; 103(29): 11057 - 11062. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Varki and T. Angata Siglecs--the major subfamily of I-type lectins Glycobiology, January 1, 2006; 16(1): 1R - 27R. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |